On life satisfaction in male erectile dysfunction

Fugl‐Meyer, Axel R.; Lodnert, G; Bränholm, Inga-Britt; Fugl-Meyer, Kerstin

doi:10.1038/sj.ijir.3900269

Cited by 244 publications

(165 citation statements)

References 5 publications

Supporting

Mentioning

145

Contrasting

Unclassified

Order By: Relevance

“…For example, it has been shown in previous studies that men with ED report deficits in several broader areas of their life, including their general emotional satisfaction, general happiness, productivity, intimacy and safety. 17,20 The psychological and QOL findings of the present study support the recent proposal by FuglMeyer et al 18 that presence of ED has its impact on men's QOL because of the creation of a sexual aspiration-achievement gap. According to FuglMeyer et al, 18 when sex is regarded as an important aspect of a man's life, but he is unable to fulfil his sexual goals (for example, through presence of ED), the gap between sexual aspirations and achievement widens, resulting in an overall decline in QOL.…”

Section: Discussionsupporting

confidence: 80%

“…7,8,18,19 It has been well demonstrated that general and healthrelated QOL of men with ED are frequently impaired, 19 and that the presence of this sexual dysfunction is associated with many different areas of a man's QOL. For example, it has been shown in previous studies that men with ED report deficits in several broader areas of their life, including their general emotional satisfaction, general happiness, productivity, intimacy and safety.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The impact of the use of PDE5 inhibitors for erectile dysfunction on the lives of Australian men

Matic

McCabe

2007

Int J Impot Res

View full text Add to dashboard Cite

This article presents findings from a recent cross-sectional study that was designed to evaluate both the impact of erectile dysfunction (ED) on the lives of Australian men, and explore whether the use of PDE5 inhibitors was able to alter this impact. The sample comprised 410 men with ED, and 242 men who did not have ED. All men were primarily recruited over the internet via men's health web sites. Participants completed a questionnaire to assess their self-esteem, masculinity, quality of life, sexual satisfaction, relationship satisfaction and usage of oral ED medication. The results demonstrated that men with ED experienced deficits on all of the psychosocial areas when compared to men without ED. Moreover, treatment with ED medication did not alleviate this deficit. Implications of these findings for the treatment of men with ED are discussed in the context of the biopsychosocial model of health and the need for a multidisciplinary approach to ED management is highlighted.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Discussionmentioning

confidence: 99%

The impact of the use of PDE5 inhibitors for erectile dysfunction on the lives of Australian men

Matic

McCabe

2007

Int J Impot Res

View full text Add to dashboard Cite

show abstract

“…Answers were scored from 1 (almost never/never) to 5 (almost always/always), with 0 indicating no sexual activity. (4) Life Satisfaction Checklist [15], week 0 and week 12; this is an 8-item questionnaire assessing the patients' quality of life (life as a whole, sexual life, partnership relation, family life, contacts with friends, leisure situation, vocational situation, financial situation). Answers are scored from 1 (very dissatisfying) to 6 (very satisfying).…”

Section: Methodsmentioning

confidence: 99%

Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus

et al. 2001

View full text Add to dashboard Cite

Diabetes mellitus is very common, with Type II (noninsulin-dependent) diabetes mellitus accounting for 90 % to 95 % of the diagnosed patients [1]. A frequent complication of diabetes is erectile dysfunction (ED), with an estimated prevalence of 20 % to 85 % (ranging from mild to complete ED) [2], which occurs at an earlier age than in non-diabetic men. In the Massachusetts Male Aging study [3], men with treated diabetes had an age-adjusted prevalence of complete ED (no erections) of 28 %, which was approximately three times higher than the prevalence of complete ED observed in the entire sample of men (10 %).Although ED in patients with diabetes is often complex and can be caused by several mechanisms Diabetologia (2001) Abstract Aims/hypothesis. Ninety percent of all men with diabetes have Type II (non-insulin-dependent) diabetes mellitus, and erectile dysfunction (ED) is common in this patient group. This study evaluated the effects of sildenafil on men with erectile dysfunction and Type II diabetes and compared the results with glycated haemoglobin concentrations and chronic diabetic complications. Methods. Patients (mean age, 59 years) in this double-blind, placebo-controlled trial were randomised to sildenafil (25±100 mg; n = 110) or matching placebo (n = 109) for 12 weeks. Primary criteria for efficacy included questions 3 (achieving an erection) and 4 (maintaining an erection) from the International Index of Erectile Function (IIEF, score range, 0±5). Secondary outcome measures included a global efficacy question (GEQ), patient event logs, a life satisfaction checklist, and the remaining IIEF questions. Results. After 12 weeks, the mean scores for questions 3 and 4 had improved significantly in patients receiving sildenafil (3.42 0.23 and 3.35 0.24) compared with placebo (1.86 0.22 and 1.84 0.23; p < 0.0001). Similarly, the GEQ score was higher in the sildenafil (64.6 %) than the placebo group (10.5 %). Even when correlating efficacy with glycated haemoglobin concentrations ( £ 8.3 % or > 8.3 %, the median concentration found in this study) or the number of diabetic complications (0 or ³ 1), the mean scores for the GEQ and questions 3 and 4 from the IIEF remained higher for all the sildenafil groups compared with the placebo groups (p < 0.0001). Conclusion/interpretation. Sildenafil was well-tolerated and effective in improving erectile dysfunction in men with Type II diabetes, even in patients with poor glycaemic control and chronic complications. [Diabetologia (2001

show abstract

“…Scores were graded on a scale of 1-5, with one for never or almost never, and five for always or almost always, with no intercourse noted as zero. In addition, the IIEF-erectile function (IIEF-EF) domain was also evaluated (the sum of Questions 1-5 plus Question 15), which ranges from severe ( £ 10), to moderate (11)(12)(13)(14)(15)(16), to mild-moderate (17)(18)(19)(20)(21), to mild (22)(23)(24)(25), to normal ( > 25). The 12-week LOCF score was used.…”

Section: Efficacy Parametersmentioning

confidence: 99%

“…. 18 Fugl-Meyer QOL scores were graded on a scale of 1-6, with one for very unsatisfying, and six for very satisfying.…”

Section: Efficacy Parametersmentioning

confidence: 99%

Safety and efficacy of vardenafil in patients with erectile dysfunction: Result of a bridging study in Japan

et al. 2004

View full text Add to dashboard Cite

Aim : Vardenafil is a selective and highly potent phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED), with improved selectivity for PDE5 and demonstrated efficacy for improving sexual function in men with ED. The current study investigated the safety and efficacy of this new PDE5 inhibitor in Japanese men with ED.Methods : This was a prospective, double blind, randomized clinical trial designed to evaluate the efficacy and safety of vardenafil. Following a 4-week treatment-free observation period, 283 eligible patients were randomized to 12 weeks treatment with vardenafil 5 mg, 10 mg, 20 mg, or placebo. Primary efficacy responses were assessed using the scores of Q3 and Q4 of the international index of erectile function (IIEF).Results : All three vardenafil doses showed significantly better improvement than the placebo group in Q3 and Q4 scores of the IIEF questionnaire, either at 12 weeks or at the 'last observation carried forward' (LOCF, P < 0.0001). Q3 scores were improved to 4.06 with vardenafil 5 mg, 4.53 with vardenafil 10 mg, and 4.64 with vardenafil 20 mg, versus 3.17 with placebo. Comparable scores for Q4 were 3.47, 4.15 and 4.31 versus 2.31 for placebo. Up to 86% of patients achieved improved erections as assessed by the global assessment question (GAQ). Reported adverse event rates were 35.3%, 45.3% and 54.5% with vardenafil 5 mg, 10 mg and 20 mg, respectively, versus 21.1% in the placebo group. No serious adverse drug reactions were reported. The most common treatment-emergent adverse events were transient headache, flushing and rhinitis, which were mostly mild. Conclusion : Vardenafil is an effective and well-tolerated treatment for ED and provides improvement in key indices of erectile function among Japanese men with ED. The results of our trial show that up to nearly 90% of patients achieve improved erections with the administration of vardenafil.

show abstract

On life satisfaction in male erectile dysfunction

Cited by 244 publications

References 5 publications

The impact of the use of PDE5 inhibitors for erectile dysfunction on the lives of Australian men

The impact of the use of PDE5 inhibitors for erectile dysfunction on the lives of Australian men

Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus

Safety and efficacy of vardenafil in patients with erectile dysfunction: Result of a bridging study in Japan

Contact Info

Product

Resources

About